1
|
Asso RN, Cury F, Rastogi N, Martinez C, Ramia P, Freeman CR. Hypofractionated Preoperative Radiotherapy 30Gy in Five Fractions for Soft Tissue Sarcoma of the Extremity. Int J Radiat Oncol Biol Phys 2023; 117:e283. [PMID: 37785056 DOI: 10.1016/j.ijrobp.2023.06.1267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Hypofractionated preoperative radiotherapy (HypoRT) is being used with increasing frequency for soft tissue sarcomas (STS) of the extremities. Besides the social and economic advantages, HypoRT has a theoretical advantage in STS because of their low α/β ratio. The objective of this study is to review our experience using HypoRT to a dose of 30Gy in 5 fractions in STS of the extremities. MATERIALS/METHODS This study is a retrospective review of patients with extremity STS treated at our center with preoperative HypoRT to a dose of 30Gy in 5 fractions given on alternate days over 2 weeks. Inclusion criteria were age ≥18 years, biopsy-proven primary STS in an extremity, and fitness for surgery. The primary endpoint was major wound complications (MWC) defined as the need for wound management or secondary operation under general or regional anesthesia within 120 days from surgery. Secondary objectives were: early toxicity grade ≥ 2 and clinical outcomes, including local control (LC), and metastasis-free survival (MFS). Descriptive statistics were used to evaluate patient and treatment characteristics. The Kaplan-Meier method was used to estimate survival. RESULTS A total of 40 patients received preoperative HypoRT at our center between 2016 and 2022. The median age was 70 years (30 - 91). Males accounted for 57.5% of the patients. The most common primary site was the lower extremity (62.5%). The most prevalent histologic type was myxofibrosarcoma (27.5%), followed by pleomorphic spindle cell sarcoma (20%). All patients were treated with image-guided intensity modulated radiotherapy with margins for the CTV as tested in the RTOG 0630 study. Median follow-up was 14.8 months (5 - 86). Acute side effects were seen in 80% of the patients, all grade <3. The most common toxicity was dermatitis (37.5%), the second was fatigue (20%), and the third was pain (15%). Surgery was performed in all cases after a median interval from completion of HypoRT of 34 days (16-59). Amputation was performed in one patient with a fungating tumor, HypoRT having been aborted at only 24Gy because of worsening symptoms. On pathologic examination, positive margins were found in four cases (10%). The percentage of necrosis was ≥ 90% in 7 patients and 50%-90% in 10. MWC occurred in 13 patients (32.5%), including 10 who underwent a procedure with anesthesia. Sixteen patients were treated for a wound infection. Only one patient recurred locally. Two-year LC was 91.7%. MFS was 87.4% at 6 months and 60.8% at 2 years. DFS was 84.9% at 6 months and 64.8% at 2 years. CONCLUSION The preoperative HypoRT regimen of 30Gy in 5 fractions given on alternate days for extremity STS is safe. Acute toxicity was not different from our previous experience using the conventional regimen of 50Gy in 25 fractions over 5 weeks and the MWC rate was comparable to that reported for the conventional regimen. Local control was excellent.
Collapse
Affiliation(s)
- R N Asso
- McGill University, Montreal, QC, Canada
| | - F Cury
- McGill University Health Centre, Montreal, QC, Canada
| | - N Rastogi
- McGill University, Montreal, QC, Canada
| | - C Martinez
- McGill University Health Centre, Montreal, QC, Canada
| | - P Ramia
- American University of Beirut Medical Center, Beirut, Lebanon
| | - C R Freeman
- McGill University Health Centre, Montreal, QC, Canada
| |
Collapse
|
2
|
Asso RN, Kopek N, Duclos M, Abdulkarim BS, Connel T, Ramia P, Saidi A, Faria SL. Toxicity of Patients with Ultra-Central Thoracic Tumors Treated with Stereotactic Body Radiotherapy (SBRT) with Dose of 50 Gy in 5 Fractions. Int J Radiat Oncol Biol Phys 2023; 117:e4. [PMID: 37785333 DOI: 10.1016/j.ijrobp.2023.06.655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) The ideal regimen for stereotactic body radiotherapy (SBRT) in ultra-central lung tumors is still to be defined, mostly due to the risk of unacceptable or fatal toxicity. There is not much information on outcomes after SBRT for this group of patients. We summarize here our experience with ultra-central lung cancer patients treated with the dose of 50 Gy delivered in 5 fractions. MATERIALS/METHODS This study is a retrospective review of all cases of ultra-central thoracic tumors treated with SBRT with the dose of 50 Gy in 5 fractions, delivered every other day, at our institution. In all cases, as we defined ultra-central lung tumor, the PTV overlapped or touched one or more of the following structures: bronchial tree, trachea, great vessels, heart, and esophagus. Metastatic and primary lung lesions were included. The volumes of treatment were defined by 4D-CT to consider breathing motion. Normal organs constraints followed the recommendations of the RTO 0813 trial as follows: Spinal cord: max 30 Gy. Lung right or lung left: V13 Gy[cc] < 1500. Esophagus: max 52 Gy and nonadjacent esophagus: V27.5 Gy[cc] < 5. Heart: V32 Gy[cc] < 15; max 52 Gy. Great vessels: max 52 Gy and non-adjacent great vessels V47 Gy[cc] < 10. Trachea plus bronchus: max 52 Gy and non-adjacent V18 Gy[cc] < 4. Follow-up, at the discretion of the treating MD, included periodic CT scans of the thorax after SBRT and assessment of radiation-induced toxicity scored with CTCv3.0. RESULTS Between December 2015 and February 2022, 86 patients were eligible for this review. Median follow-up was 17 months (range: 1-76 months); the median age was 74 years (range: 37-98 years). Histology was as follows: 50 patients had biopsy proved NSCLC, 16 had no biopsy, and 20 had metastatic non-lung primaries. Overlapped structures were as follows: with great vessels in 46 cases, heart in 20 cases, trachea/branchial tree in 18 cases, and esophagus in 2 cases. In 16 patients the overlap was present in more than one structure. Overall, 68.6% did not report acute toxicity. The most common acute side effects were fatigue (15.1%), coughing (8.1%), shortness of breath (6.9%), esophagitis (2.3%), and dysphagia (1.1%). No grade 3 or more significant toxicity was described. As acute side effects, many patients had exacerbations of the previous condition, such as shortness of breath (16 pts) or coughing (4 pts) during follow-up. Pneumonitis was found as a late side effect in four cases. One patient had empyema associated with a fistula in the non-irradiated lung, where the patient had previous surgery, but in the irradiated lung no severe complication was detected. There were no deaths attributed to the SBRT treatment. 67.5% of 86 patients were alive at the time of the review; 87.2% had local control, and 65.1% had metastases-free survival. CONCLUSION In this cohort of patients, no death or even severe acute or chronic toxicity was attributed to SBRT. SBRT seems safe for ultra-central lesions using the regimen of 50 Gy in 5 fractions with the constraints of the RTOG 0813 trial.
Collapse
Affiliation(s)
- R N Asso
- McGill University Health Centre, Montreal, QC, Canada
| | - N Kopek
- McGill University Health Centre, Division of Radiation Oncology, Montreal, QC, Canada
| | - M Duclos
- McGill University Health Centre, Division of Radiation Oncology, Montreal, QC, Canada
| | - B S Abdulkarim
- McGill University Health Centre, Division of Radiation Oncology, Montreal, QC, Canada
| | - T Connel
- Medical Physics Unit, McGill University, Montreal, QC, Canada
| | - P Ramia
- American University of Beirut Medical Center, Beirut, Lebanon
| | - A Saidi
- McGill University Health Centre, Department of Radiation Oncology, Montreal, QC, Canada
| | - S L Faria
- McGill University Health Centre, Montreal, QC, Canada
| |
Collapse
|
3
|
Ramia P, Mkanna A, Shahine B, Makke Z, Hilal L, Geara F, Adel M, Olleik F, Youssef B. PO-1202: CHHiPvsPROFIT for Localized Prostate Cancer:A Retrospective Dosimetric Comparison of Organs at Risk. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01220-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
4
|
Chehab O, Pahuja M, Adegbala O, Akintoye E, Ramia P, Morsi R, Alrojolah L, Mishra T, Shokr M, Kanj A, Abdallah N, Tabaja H, Afonso L, Abidov A. P3603Impact of idiopathic thrombocytopenic purpura on clinical outcomes in patients with acute myocardial infarction. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
There is scarce evidence reflecting the clinical outcomes in patients with Idiopathic Thrombocytopenic Purpura (ITP) and Acute Myocardial Infarction (AMI). The ITP patient population is at higher risk of bleeding complications due to low platelet counts and difficulty in managing their antiplatelet and anticoagulation therapy. In our study, we sought to assess clinical outcomes of ITP patients admitted with AMI using the US national inpatient sample (NIS) database.
Purpose
To determine difference in in-hospital mortality, clinical complications, and length of stay (LOS) in AMI patients with and without ITP.
Methods
We identified adults aged ≥18 years hospitalized from 2005 to 2014 with AMI as their primary diagnosis utilizing ICD-9 codes 410.0 to 410.92. Patients with ITP were identified using ICD-9 code 287.31. The primary outcome was in-hospital mortality. Secondary outcomes included coronary revascularization procedures (PCI and CABG), and in-hospital complications including bleeding (intracranial, epistaxis, GI, and GU bleeding, hematoma, and bleeding requiring transfusion), cardiac complications, transfusions, acute ischemic stroke (AIS), and LOS. A propensity-matched cohort accounting for demographic characteristics, comorbidities, and cardiovascular risk factors, was created to compare these outcomes. Patients with secondary causes of ITP such as HIV, pregnancy, sepsis, SLE, malignancy were excluded.
Results
A total of 1108034 AMI admissions, of which 1002 with ITP, were identified. In the unmatched group, patients with ITP were older, and had more comorbidities (diabetes mellitus; hypothyroidism; atrial fibrillation; previous history of cardiovascular, peripheral, and end stage renal disease; all p<0.05). In the AMI population, 851 ITP and 851 non-ITP admissions were propensity-matched. Figure 1 illustrates the primary and secondary outcomes of the study among the propensity-matched study groups. Although there was no difference in short-term mortality between the ITP and non-ITP patients with AMI, patients with ITP were less likely to undergo coronary revascularization possibly because of thrombocytopenia. Patients with ITP had significantly more bleeding complications and transfusions. We observed in our study that patients with ITP had a significantly longer LOS compared to non-ITP patients (6.1 vs 5.4 days, with a mean ratio of 1.14 (95% CI: 1.05,1.23)).
Conclusion
In the large population of patients included in the NIS database, patients with ITP admitted with AMI, have a significantly higher rate of bleeding complications, undergo less PCI and have a longer LOS compared to AMI patients without ITP. There are no current guidelines by ACC/AHA/ESC regarding management of patients with AMI and thrombocytopenia. These results warrant further investigation through randomized controlled trials including patients with thrombocytopenia to assess long term outcomes and to define optimal management in this population.
Collapse
Affiliation(s)
- O Chehab
- Wayne State University, Detroit, United States of America
| | - M Pahuja
- Wayne State University, Detroit, United States of America
| | - O Adegbala
- Wayne State University, Detroit, United States of America
| | - E Akintoye
- Wayne State University, Detroit, United States of America
| | - P Ramia
- American University of Beirut AUB, Beirut, Lebanon
| | - R Morsi
- Harvard Medical School, Boston, United States of America
| | - L Alrojolah
- American University of Beirut AUB, Beirut, Lebanon
| | - T Mishra
- Wayne State University, Detroit, United States of America
| | - M Shokr
- Wayne State University, Detroit, United States of America
| | - A Kanj
- Wayne State University, Detroit, United States of America
| | - N Abdallah
- Wayne State University, Detroit, United States of America
| | - H Tabaja
- Wayne State University, Detroit, United States of America
| | - L Afonso
- Wayne State University, Detroit, United States of America
| | - A Abidov
- Wayne State University, Detroit, United States of America
| |
Collapse
|
5
|
Bergqvist C, Ramia P, Abbas O, Kurban M. Genetics of syndromic and non-syndromic hereditary nail disorders. Clin Genet 2016; 91:813-823. [PMID: 27613389 DOI: 10.1111/cge.12852] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2016] [Revised: 08/22/2016] [Accepted: 08/22/2016] [Indexed: 01/18/2023]
Abstract
The nail is a unique epithelial skin appendage made up of a fully keratinized nail plate. The nail can be affected in several systemic illnesses, dermatological diseases, and inherited nail disorders. Nail dystrophies can present as isolated disorders or as a part of syndromes. Substantial progress has been achieved in the management and diagnosis of nail diseases; however, not much is known about the underlying molecular controls of nail growth. The homeostasis and development of the nail appendage depend on the intricate interactions between the epidermis and underlying mesenchyme, and comprise different signaling pathways such as the WNT signaling pathway. Digit-tip regeneration in mice and humans has been a known fact for the past six decades; however, only recently the underlying biological mechanisms by which the nail organ achieves digit regeneration have been elucidated. Moreover, significant progress has been made in identifying nail stem cells and localizing stem cell niches in the nail unit. More fascinating, however, is the role they play in orchestrating the processes that lead to the regeneration of the digit. Further elucidating the role of nail stem cells and the signaling pathways driving epithelial-mesenchymal interactions in the nail unit might contribute to the development of novel therapeutic tools for amputees.
Collapse
Affiliation(s)
- C Bergqvist
- Department of Dermatology, American University of Beirut, Beirut, Lebanon
| | - P Ramia
- Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
| | - O Abbas
- Department of Dermatology, American University of Beirut, Beirut, Lebanon
| | - M Kurban
- Department of Dermatology, American University of Beirut, Beirut, Lebanon.,Department of Biochemistry and Molecular Genetics, American University of Beirut, Beirut, Lebanon.,Department of Dermatology, Columbia University Medical Center, New York, NY, USA
| |
Collapse
|